Samuel A Wells

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update
    Samuel A Wells
    Jr, MD, Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814
    J Clin Endocrinol Metab 98:3149-64. 2013
  2. doi request reprint Targeting the RET pathway in thyroid cancer
    Samuel A Wells
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7119-23. 2009
  3. pmc Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
    Samuel A Wells
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 30:134-41. 2012
  4. doi request reprint Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases
    Anna Tamburrino
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:3532-40. 2012

Collaborators

Detail Information

Publications4

  1. doi request reprint Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update
    Samuel A Wells
    Jr, MD, Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814
    J Clin Endocrinol Metab 98:3149-64. 2013
    ..Information gained from molecular testing, biochemical analysis, and clinical evaluation is important in providing effective management of patients with either early or advanced-stage MTC. ..
  2. doi request reprint Targeting the RET pathway in thyroid cancer
    Samuel A Wells
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7119-23. 2009
    ..Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy...
  3. pmc Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
    Samuel A Wells
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 30:134-41. 2012
    ....
  4. doi request reprint Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases
    Anna Tamburrino
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:3532-40. 2012
    ..Understanding the molecular pathogenesis of medullary thyroid carcinoma (MTC) is prerequisite to the design of targeted therapies for patients with advanced disease...